The estimated Net Worth of Jeffrey Hessekiel is at least $26.7 Million dollars as of 26 August 2024. Mr Hessekiel owns over 20,000 units of Exelixis Inc stock worth over $17,318,155 and over the last 11 years he sold EXEL stock worth over $8,434,510. In addition, he makes $916,910 as Exec. VP and Gen. Counsel & Sec. at Exelixis Inc.
Mr has made over 33 trades of the Exelixis Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of EXEL stock worth $488,200 on 26 August 2024.
The largest trade he's ever made was exercising 249,692 units of Exelixis Inc stock on 8 September 2020 worth over $1,293,405. On average, Mr trades about 26,600 units every 45 days since 2014. As of 26 August 2024 he still owns at least 650,325 units of Exelixis Inc stock.
You can see the complete history of Mr Hessekiel stock trades at the bottom of the page.
Jeffrey J. Hessekiel is the Exec. VP, Gen. Counsel & Sec. at Exelixis Inc.
As the Exec. VP and Gen. Counsel & Sec. of Exelixis Inc, the total compensation of Mr Hessekiel at Exelixis Inc is $916,910. There are 5 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.
Mr Hessekiel is 52, he's been the Exec. VP and Gen. Counsel & Sec. of Exelixis Inc since . There are 16 older and 4 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Over the last 22 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey, and Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: